Management ChangeApr 23, 2026, 06:01 AM
BridgeBio Oncology Appoints Pedro Beltran as New CEO & Director
AI Summary
BridgeBio Oncology Therapeutics, Inc. announced the appointment of Pedro Beltran, Ph.D., as its new President and Chief Executive Officer, effective April 20, 2026. Dr. Beltran also joins the Board of Directors as a Class III director. He succeeds Eli Wallace, Ph.D., who resigned from his CEO and director positions but is expected to continue as an advisor to the company. Dr. Wallace's resignation was not due to any disagreement with the company's policies.
Key Highlights
- Pedro Beltran, Ph.D., appointed President and CEO, effective April 20, 2026.
- Dr. Beltran also appointed as a Class III director.
- Eli Wallace, Ph.D., resigned as President, CEO, and Class III director.
- Dr. Wallace will continue as an advisor to the Company.
- Dr. Beltran previously served as Chief Scientific Officer since April 2024.
Price Impact
More from BBOT